Scientists hunt for clues to predict blood cancer treatment success
NCT ID NCT05440838
Summary
This study aims to discover biological markers that can predict which patients with certain blood cancers will respond well to standard first-line treatments. Researchers will analyze blood samples from 120 adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis to look for genetic and immune system patterns. The goal is to help doctors identify patients who might need different treatments sooner, moving toward more personalized medicine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Angers
RECRUITINGAngers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Brest
RECRUITINGBrest, 29606, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Nantes
RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Poitiers
RECRUITINGPoitiers, 86021, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Rennes
RECRUITINGRennes, 35033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Tours
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.